Trials / Unknown
UnknownNCT04470947
Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies
Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies: Next Generation Personal Hematology
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice
Conditions
- Advanced Lymphoma
- Refractory Lymphoma
- Refractory Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory T-Cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Next generation functional drug screening | High-throughput image based in-vitro drug screening on primary patient tumor cells |
| DIAGNOSTIC_TEST | Comprehensive genomic profiling | Comprehensive targeted profiling of genetic aberrations on primary patient tumor material |
Timeline
- Start date
- 2020-06-10
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2020-07-14
- Last updated
- 2024-03-22
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT04470947. Inclusion in this directory is not an endorsement.